• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Avient (AVNT) A Bargain As Strong Earnings Put Its Valuation In Focus?

    Simply Wall St·08/19/2026 23:41:23
    语音播报

    Avient (AVNT) drew investor attention after reporting second quarter 2026 results, with sales of US$917 million and net income of US$64.8 million, along with higher earnings per share from continuing operations versus last year.

    See our latest analysis for Avient.

    Avient's latest earnings update came alongside a strong 30 day share price return of 22.6% and a 39.6% share price return year to date. The 1 year total shareholder return of 28.7% points to momentum that has been building rather than fading.

    If Avient's recent move has you rethinking where growth could come from next, it may be worth scanning other AI infrastructure plays through the 55 AI infrastructure stocks

    After this kind of move in Avient, investors often wonder whether they are mainly looking at gains already booked or if value on offer still lines up with further upside. The next step is to test what the current valuation implies.

    Most Popular Narrative: 11% Undervalued

    Avient's most followed valuation narrative pegs fair value at $49.71, above the last close of $44.26, which frames the recent share price strength in a different light.

    Accelerating demand for high-performance, specialty materials in healthcare devices, drug delivery, and equipment, driven by global healthcare expansion and innovative new product launches, positions Avient for resilient, long-term revenue growth and increased net margins due to higher-value, spec-in solutions.

    Read the complete narrative.

    Curious what sits behind that fair value gap. The narrative leans heavily on a step up in earnings power, margin expansion, and a future earnings multiple reset. The precise mix of growth, profitability, and discount rate assumptions is where the story gets interesting.

    Result: Fair Value of $49.71 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, the Avient narrative could quickly change if raw material costs remain volatile or if key end markets weaken and put pressure on the current margin assumptions.

    Find out about the key risks to this Avient narrative.

    Another View On Avient Using Earnings Multiples

    The Simply Wall St fair value model estimates Avient as 31.5% undervalued at $44.26, while the stock trades on a P/E of 23.9x versus a fair ratio of 21.8x. This is lower than the US Chemicals industry at 25.9x and peers at 29.5x, but it still reflects a significant amount of anticipated progress. How comfortable are you with that trade off?

    See what the numbers say about this price — find out in our valuation breakdown.

    NYSE:AVNT P/E Ratio as at Aug 2026
    NYSE:AVNT P/E Ratio as at Aug 2026

    Next Steps

    With both risks and rewards in play for Avient, this is a moment to review the data yourself and move quickly on your own judgment. To see both sides laid out clearly, start with the 4 key rewards and 2 important warning signs.

    Looking for more investment ideas beyond Avient?

    If you stop with Avient, you could miss other opportunities that fit your style. Use the Simply Wall St Screener to broaden your watchlist thoughtfully.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.